Brain tumorsVparticularly glioblastoma multiformeVpose an important public health problem in the United States. Despite surgical and medical advances, the prognosis for patients with malignant gliomas remains grim: current therapy is insufficient with nearly universal recurrence. A major reason for this failure is the difficulty of delivering therapeutic agents to the brain: better delivery approaches are needed to improve treatment. In this article, we summarize recent progress in drug delivery to the brain, with an emphasis on convection-enhanced delivery of nanocarriers. We examine the potential of new delivery methods to permit novel drug-and gene-based therapies that target brain cancer stem cells and discuss the use of nanomaterials for imaging of tumors and drug delivery.
I mproved methods for treating glioblastoma multiforme (GBM) and other malignant tumors in the brain are desperately needed. Malignant gliomas are the most common primary malignant brain tumors in adults. More than 15,000 new cases are diagnosed in the United States each year. 1, 2 Despite surgical and medical advances, the 5-year survival rate for GBM, the most common malignant glioma, has been a dismal 4% for the past few decades. 3, 4 Current treatments for GBM are insufficient with a nearly universal recurrence after surgery, radiation therapy, and chemotherapy. 5 A major problem in the therapy for GBM and other central nervous system diseases is getting drugs into the brain. The bloodbrain barrier (BBB) prevents the transport of most systemically delivered molecules into the brain. Recent research has created better methods for drug delivery to the brain. Here, we review the state-of-the-art in the development of new approaches for drug delivery to the brain, highlighting those methods that are most relevant to GBM.
CONTROLLED RELEASE SYSTEMS FOR DELIVERY TO THE BRAIN
The BBB limits the entry of systemically administered drugs to the brain, making delivery behind the BBB an appealing strategy. One method for accomplishing delivery behind the BBB is implantation of a drug-eluting material into the brain tissue. Controlled release systems for direct delivery of chemotherapy to brain tumors were first approved by the Food and Drug Administration (FDA) in 1996. 6, 7 The rationale for this approach is that biocom-patible materials can be introduced directly into the brain, perhaps during surgical resection of the tumor. If the materials are loaded with drugs and are engineered such that the drug is slowly released after implantation, then their implantation into the brain can provide long-term chemotherapy at the tumor site, circumventing the need for BBB penetration. In this approach, drug penetrates into the tissue near the implant by diffusion, producing the highest drug concentrations in the region most in need of treatment and eliminating adverse effects caused by delivery of drug to other tissues (Fig. 1A) .
The most successful controlled release systems are based on biocompatible polymers, particularly polymers that are also biodegradable. The first clinical trials of this approach used a 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)Yloaded polyanhydride delivery system 8Y11 : BCNU is an alkylating agent, which was the most commonly used chemotherapy drug for GBM in the 1990s. An early clinical study demonstrated that the procedure was safe, 12 and a subsequent placebo-controlled clinical trial showed that implantation of BCNU-loaded polymers was more effective than standard therapies in patients with recurrent GBM. 13 This new method for brain tumor therapy was rapidly adopted (the clinical product is called Gliadel, Eisai, New Jersey), leading to dozens of clinical studies by investigators around the world and improved life span for many brain tumor patients. Experimental controlled delivery systems have been produced with a variety of other compounds, including methotrexate, 14 paclitaxel, 10,15 steroids, 16 and camptothecin (CPT), 17 but so far none have been tested in humans.
The safety and effectiveness of this new approach for treating GBM have been established, but the increases in survival observed in clinical trials with Gliadel are modest. However, diffusion-based implant systemsVsuch as GliadelVcan produce substantial increases in the duration of survival of animals, and optimal formulations can eliminate tumors in animal models. Implantation of a single polymer implant in the brain of an animal produces unprecedented concentrations of active BCNU within the tissue near the implant. 10, 11 The contrast between these observations in animal models and clinical studies suggests that one of the limitations of Gliadel is the small volume treated by diffusion-based delivery systems.
CONVECTION-ENHANCED DELIVERY TO THE BRAIN
Convection-enhanced delivery (CED) is a promising approach to overcome the limited distribution volume associated with diffusion-based delivery systems. For diffusion-based delivery, drug molecules move passively from regions of high concentration to regions of lower concentration. As a result, large molecules such as antibodies diffuse no more than 1 mm in 3 days, and small drugs that may have better diffusion are often quickly eliminated by capillary clearance or metabolism. 18 In contrast, for dispersion using convection, agents are delivered to the brain via flow through a cannula under constant pressure. In this scenario, the dispersion of agents is powered by bulk flow kinetics or gradients of pressure, in addition to gradient of concentrations. As a result, it is possible to distribute agents widely in the brain (Fig. 1B ). Convection-enhanced delivery technology and factors affecting drug distribution by CED have been extensively reviewed 18, 19 and thus will not be discussed in detail here.
Convection-enhanced delivery to the brain was first reported in the early 1990s. 20 Since then, CED has been used in clinical trials, but this experience has revealed some limitations. Conventional CED of drug solutions results in an increased depth of penetration, but these results are transient. Free drugs are subject to high rates of elimination (i.e., they are transported into cerebrospinal fluid or blood) or have short half-lives in the brain; therefore, they disappear soon after the infusion stops. 18 Interstitial fluid flow might particularly impact CED of free agents to brain tumors. Mathematical modelsVand some experimental evidenceVsuggest that tumors maintain an elevated interstitial fluid pressure in their cores, 21 which produces an outwardly directed flow of extracellular fluid at their periphery. 22 These limitations could explain the failure of the recent PRECISE trial, in which a potent targeted toxin, CB (cintredekin besudotox, IL13-PE38QQR) in aqueous suspension, was delivered to brain tumors via CED but failed to show advantage when compared with diffusion-based Gliadel wafers. 23 To improve CED, agents can be loaded into nanocarriers, such as liposomes, micelles, dendrimers, or polymeric nanopar-ticles, which are small enough (typically 100Y200 nm in diameter) to allow for infusion and penetration in brain. These carriers can protect therapeutic agents from loss and control their release for long periods after infusion ( Fig. 2 ). Nanoparticle delivery systems for drugs have been available for many years. 25 Some research groups focus on the use of nanoparticles introduced systemically, with the hopes that some of these particles will enter the brain through the BBB. This approach appears to work in some cases, but the percentage of intravenously administered particles that enter the brain is very low. 26Y28 It is not yet clear whether sufficient quantities of drug can be delivered by systemically administered nanoparticles to make this a useful method for treating tumors in the brain (although there is some evidence that systemically administered nanoparticles may be useful for diagnostic purposes, such as iron oxideYcontaining nanoparticles that facilitate imaging of brain tumors 29 ). An alternate approach is to deliver the nanoparticles directly into the brain, perhaps using CED to facilitate the distribution of the nanoparticles throughout the volume of the brain that needs therapy (Fig. 1C ).
Convection-enhanced delivery of lipid-based nanoparticle systems, such as liposomes, has been well studied. Liposomes are artificial phospholipid vesicles that form a ''core-shell'' structure and can be readily loaded with therapeutic agents. Convection-enhanced delivery of liposomes has been evaluated in rat brain tumor xenografts 30Y33 and canine spontaneous brain tumors 34 ; CED has also been tested in the normal brain of nonhuman primates. 35, 36 Compared with CED of free drugs, CED of liposomes increases the distribution of delivered agents, 37 reduces toxicity, and extends half-life. 32,34,38 Convection-enhanced delivery of liposomes has recently been tested in human GBM patients: it appears to be safe and to provide some therapeutic benefit. 39, 40 As an alternate to liposomes, polymer nanoparticles can be delivered via CED. In a recent study, CED of CPT-loaded nanoparticles led to longer survival in animals with intracranial tumors than CED of CPT alone. 41 Previous efforts to deliver polymer nanoparticles via CED have achieved a limited volume of distribution, because of an inability to fabricate polymer nanoparticles of small-enough size to allow for unhindered interstitial convective transport. 41, 42 The pore size of the normal brain extracellular space is 38 to 64 nm 43 versus È70 to 100 nm within a tumor in the brain, 44 which suggests that nanoparticles for CED to intracranial tumors should be 60 to 80 nm in diameter to allow for access to tumorous tissue while sparing the normal brain. We recently developed methods for fabricating nonaggregrating poly(lactide-co-glycolide) (PLGA) nanoparticles of this size. 45 Our data suggest that these nanoparticles are able to penetrate brain tissue with a mean volume of distribution that is at least 10-fold larger than previously published formulations (J. Zhou unpublished data).
NEW DELIVERY TECHNOLOGIES CREATE OPPORTUNITIES FOR DRUG THERAPY
The most recent advance in drug therapy of GBM was the FDA approval in 2005 of temozolomide (TMZ), which has since replaced BCNU as standard therapy. Both TMZ and BCNU cross the BBB, but TMZ produces fewer adverse effects and is bioavailable after oral administration (BCNU is administered by infusion or through implantation of Gliadel). 46Y48 Even with these drugs, the median survival for GBM patients is less than 15 months: drug resistance and tumor recurrence remain major challenges.
In the past, drugs needed to cross the BBB to be candidates for use in treating GBM. New delivery technologiesVsuch as implantable controlled release systems, CED, and nanoparticlesV make it possible to use drugs that do not cross the BBB into the brain. These technologies create a new opportunity: drugs can be selected based solely on their potential for effectiveness against tumors, without regard for their ability to cross the BBB. For example, it is now clear that paclitaxelVwhich does not cross the BBBVis an effective agent for treating brain tumors when administered via paclitaxel-loaded implants or CED of paclitaxel nanoparticles or microparticles. 15, 49 Likewise, CED permitted the clinical testing of immunotoxins, which do not cross the BBB, in the PRECISE trial. 23 Many experimental drugs are currently being examined for treatment of GBM (Table 1) : these agents target a wide variety of molecular pathways important in glioma cell survival. But few of these agents will cross the BBB at doses sufficient to treat tumors in the brain without systemic adverse effects. Therefore, using conventional methods of drug delivery (infusion or oral administration), these novel agents will likely suffer from the same problem that has plagued drug therapy of brain tumors for decades: it will be difficult to deliver these agents to human tumors at a sufficient dose for effectiveness without also creating serious toxicity. New delivery systems may enhance the clinical value of some of these agents, by allowing sustained local delivery that concentrates the drug at the target.
Furthermore, it is becoming increasingly clear that certain cells within tumors play a major role in tumor progression and that these cells are not sensitive to current drugs. 123, 124 A small fraction of glioma cells has been identified as brain cancer stem cells (BCSCs), of which many are CD133+. 125Y132 These cells have features similar to primitive neural stem cells, but they also have tumor-initiating functions. 133 BCSCs appear to arise from deranged neural stem cell or glial cell progenitors 124Y128 : these cells have the ability to drive tumor formation, promote angiogenesis, and influence tumor cell migration. 124, 129, 134 Current chemotherapeutic agents do not eliminate BCSCs effectively 123, 135, 136 : BCSCs in culture are resistant to standard chemotherapy drugs, including TMZ, carboplatin, cisplatin, paclitaxel, doxorubicin, vincristine, methotrexate, and etoposide. 137Y140 BCSCs are also resistant to standard radiotherapy. 129 These observations suggest that current therapeutic regimens may produce short-term remissions but are unlikely to cure GBM: long-term remissions require eradication of BCSCs. 123, 124, 135, 141 One promising approach to identifying novel therapies for BCSCs is to target key signaling pathways governing BCSC proliferation and self-renewal, such as the PTEN/PI3K (phosphatidylinositol 3-OH kinase)/Akt pathway. 142 Inhibition of the Akt pathway induces BCSC differentiation and inhibits selfrenewal and tumorigenicity in vivo. 50, 143 Developmental pathways, including the Notch 144,145 and BMP pathways, 146 are important for BCSC self-renewal and differentiation and can be targeted to preferentially eliminate BCSCs. In addition, several other signaling pathways, including epidermal growth factor receptor (EGFR), 147 transforming growth factor receptor, 148 and hypoxia-inducible factor, 149 are critical for BCSC proliferation, survival, and self-renewal. An alternate approach is to take advantage of recent advances in genomics and informatics to identify therapeutic agents via high-throughput screening. For example, an RNAi screen against a kinome library successfully identified TRRAP as a regulator of BCSC differentiation. 150 More recently, 8 small molecule drugs that preferentially inhibit BCSCs from GBM over tumor-matched non-BCSC GBM cells were identified from a library of more than 30,000. 103 These early successes suggest that high-throughput screening is a promising approach for identifying novel BCSC-targeted therapeutics. Some of the most promising drugs now being examined for GBM therapy (Table 1) were identified through their activity on BCSCs.
Delivery remains a major obstacle for use of any agent that targets BCSCs. The new delivery technologies described earlier will likely prove necessary for translating these agents to clinical practice.
DELIVERY SYSTEMS FOR GENE THERAPY
The promise of gene therapy in GBM has long been known, but the difficulty carrying it out is equally well recognized. An early gene therapy approach involved introduction of genes at the tumor site that would activate systemically administered prodrugs. 151 One such system, which used herpes simplex virus thymidine kinase and ganciclovir, showed success in mouse models, 152, 153 but in a phase III trial, postoperative delivery failed to show benefit compared with postoperative radiotherapy. 154 Other approaches have since emerged, particularly since the recognition of the role of microRNA (miRNA) in tumors and the power of RNA interference for silencing genes.
A variety of gene therapy approaches may be useful in GBM. Deletion of known tumor suppressors, such as PTEN, is a common mechanism of gliomagenesis. 155 Rescued expression of PTEN in U87 glioma cells suppresses tumorigenicity in vivo and promotes entry into G1 phase of the cell cycle. 156 Genes in the tumor-suppressing p53 pathway, 157, 158 such as TP53, MDM2/4, and p14-ARF, and the retinoblastoma (Rb) pathway, 157, 159 such as Rb, CDK4/6, and p16-INK4A, are also promising targets for treatment of GBM. Alternately, brain tumor growth can potentially be inhibited by blocking expression of genes, such as Information was compiled from a variety of sources including clinicaltrials.gov (indicated by ClinicalTrials.gov identifiers such as NCT01051557), Adamson et al., 47 Visnyei et al, 103 and individual references as listed.
mTOR indicates mammalian target of rapamycin; LDL, low-density lipoprotein; PKCB, Protein kinase C beta; STK, serine/threonine kinase.
EGFR. 160 High-throughput sequencing efforts and the compilation of data into The Cancer Genome Atlas, as well as the development of the Cancer Bioinformatics Grid, have led to the identification of a number of highly novel chromosomal mutations, amplifications, and deletions that are important in GBM. 157 Chief among them is mutation to isocitrate dehydrogenase 1 and 2. 161 Mutated isocitrate dehydrogenase 1 leads to induction of the hypoxia-inducible factor pathway, 162 which leads to an increased fraction of BCSCs. 163 MicroRNAs play important roles in gliomagenesis and can be targets for treatment. Reduced expression of a number of miRNAs has been noted in GBM. 164 miR-7 is capable of repressing EGFR signaling, 165 so rescue or ectopic expression of miR-7 in tumor cells may limit GBM progression. Expression of miR-221, an antiapoptotic factor, is markedly elevated in human GBM tissues, 166 and inhibition of miR-221 decreases tumor growth in tumor xenograft. 167 miR-10b, which inhibits cell cycle arrest and apoptosis while promoting growth through p16-INK4A and p21 targeting, is another miRNA known to be elevated in GBM tissue samples and cell lines. 168 Several other miRNAs are important for brain tumor cell survival and represent potential targets for therapy. 169, 170 Delivery remains the major obstacle for gene-based therapies. Viral vectorsVincluding retrovirus, 154 adenovirus, 171 and adeno-associated virus 172, 173 Vare often used in evaluations in animals or humans, because of their high transduction efficiency. In addition to safety concerns, free viral particles in suspension may not reach disseminated tumor cells. 174, 175 Synthetic nonviral vectors, such as nanoparticle-based gene delivery vehicles, might be a better approach because of their limited immunogenicity, ability to accommodate and deliver large pieces of genetic material, and potential for modification of their surface structures to allow targeting. Among nonviral vectors, cationic lipid-based systems, including liposome and solid lipid nanoparticles, are the most extensively studied. 176, 177 Liposome-based gene delivery vehicles have been used for gene therapy to brain tumors in animals 178, 179 and have shown some promise in clinical trials. 39, 40, 180 Cationic polymers, such as dendrimer- 181, 182 and polyethyleneimine-based nanocarriers, 183 also have potential for gene delivery to brain tumors. But these highly charged vectors are usually toxic; because of excess positive charge at their surface, these nanocarriers inhibit normal cellular processes, such as clathrin-mediated endocytosis 184 and cell survival signaling, 185 leading to substantial toxicity. 184, 186, 187 Most lipid and polymer gene delivery systems rely exclusively on cation density to form complexes with DNA. But it has recently been discovered that the ability of polymer nanocarriers to deliver genes depends on factors other than charge density, particularly polymer molecular weight and hydrophobicity. High molecular weight and increased hydrophobicity can compen-sate for low charge density to provide efficient gene delivery with minimal toxicity. 188, 189 For example, poly (amine-co-ester) terpolymers, which have significantly lower charge density than traditional polycationic polymers, are able to deliver genes in vitro and in vivo with efficiency superior to existing commercially available gene delivery systems and with limited toxicity. 190 Another approach for developing safe and efficient polymerbased vehicles is to start with polymers that are known to be safe for clinical use and to modify them to enhance their ability to deliver genes or oligonucleotides. Poly(lactide-co-glycolide) was approved by FDA in 1969 and has been in continuous clinical use since that time. Octafunctional nanoparticles were produced by modification of PLGA nanoparticles through the use of chemical conjugation and physical formulation techniques. These nanoparticles exhibit limited toxicity but are able to efficiently deliver DNA or siRNA to tumor cells in vitro and in vivo, 191 making them suitable for brain tumor gene therapy.
IMAGING OF DRUG DELIVERY IN THE BRAIN
Accurate measurement of the distribution of a delivered agent is needed to assess drug or gene delivery in GBM. Magnetic resonance imaging (MRI) allows for monitoring of delivery in certain cases. Recent studies have used diffusion-weighted imaging (DWI) as a means to monitor the administration of fluid into the brain; it is assumed that the location of changes in DWI correlates to the area occupied by infused drug. These studies find an area of decreased diffusion immediately after infusion that evolves into an area of increased fluid movement. 192, 193 In the setting of CED, where many factors can influence the distribution of the infusion, this finding is particularly useful: optimizing fluid distribution is needed for effective treatment. 193 Significantly, DWI is frequently used in the clinical setting and does not require the administration of contrast agents. But DWI must be used with caution: it relies on water movement to produce signal changes, effectively only in measuring the movement of the solvent and measuring it indirectly. There is also debate as to the mechanisms producing the observed intensity changes and whether they represent the infusate or reactive fluid movement. 194 Drug distribution can be quantified by MRI using gadoliniumbased contrast agents. Contrast provided by gadolinium agents, such as gadolinium-diethylene triamine pentaacetic acid (Gd-DTPA), can be used to monitor disruption of the blood-brain barrier. 195 When coadministered with a therapeutic agent or other macromolecule ( Fig. 3) , Gd-DTPA can be used to assess the volume of drug delivery. 195, 196 Gadolinium complexes can be conjugated to or encapsulated in nanocarriers, such as polymer nanoparticles 197, 198 or liposomes, 30, 35 to assess the dispersion of drugloaded particles. This approach is appealing, but it has limitations. Gadolinium contrast agents are smaller than many delivery vehicles. Thus, when used as surrogates, they can diffuse over a larger volume than the actual agent (although, in practice, this effect may be small). 195, 196, 199 Some groups have addressed this issue by conjugating therapies to materials that can be imaged directly, such as iron-oxide nanoparticles. 200 But this approach can also present problems, because the addition of an imaging moiety can alter the agent in unforeseen ways, such that distribution behavior does not precisely mirror the natural, unmodified agent. Contrast agentYderived signals are more easily related to drug movement than diffuse signaling changes, such as those seen on DWI, but they have limitations.
Nuclear medicine imaging can also be used to monitor drug distribution. In single-photon emission computed tomography (SPECT), a F-emitting tracer, allows for 3-dimensional visualization of the distribution area of an agent. 195, 201 The radioisotope can be either coadministered with the drug of interest or directly bound to the biologically active molecule (such as siRNA) to allow for direct assessment of its volume of distribution. 202 Single-photon emission computed tomography imaging can be coupled with computed tomography or MRI for anatomic correlation. 202 This approach is direct and uses equipment that is significantly less expensive than those used in other nuclear medicine imaging techniques. 203 The main drawback of conventional SPECT is resolution, although recent advances in hardware (such as pinhole SPECT) allow for resolution at the millimeter level. 204, 205 Positron emission tomography (PET) is another promising modality for imaging drug delivery to tumors. As with gadolinium and SPECT contrast agents, PET tracers can be infused concurrently with drug or bound to the delivery system, such as nanoparticles. 206Y208 When PET is coupled with computed tomography, molecular movement can be correlated with anatomy, allowing for measurement of the anatomic area of diffusion of tracer or tracer-laden substance. 206, 207 Furthermore, through the use of tracers that are derivatives of amino acidsVsuch as O-(2-[ 18 F]fluoroethyl)-L-tyrosineVPET imaging can estimate the borders of a tumor, allowing for more accurate assessment of drug distribution relative to tumor volume than MRI. 206, 209, 210 Challenges for PET imaging include radiation exposure (which is also a challenge in SPECT), the high cost of the studies, and the short-lived nature of typical PET tracers. 211 Another limitation is similar to the one mentioned for gadolinium agents in MRI: unless the tracer is directly coupled to the delivery agent, then the measurement of the area of diffusion is indirect. Direct radiolabeling of nanoparticles shows that it is possible to overcome this limitation. 212 
CONCLUSIONS
New drug delivery strategies are already impacting treatment of GBM, and it seems clear that delivery systems will be needed for therapies of the future, which will be targeted to particular cells and depend on intracellular delivery of agents that do not readily cross the BBB or enter cells. Polymer implants, CED techniques, and degradable nanoparticles are powerful platform technologies for creation of new methods to treat GBM. 25 
